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Abstract
Aim. The prevalence of risk factors for cardiovascular and metabolic diseases was inves-
tigated in an adult population of the city of Cittanova, Southern Italy. 
Methods. The study was conducted among 992 randomly selected adults aged 18-75 
years, between April 2009 and January 2011. 
Results. Prevalence rates of non-alcoholic fatty liver disease (NAFLD), overweight, obe-
sity, and metabolic syndrome (MS) were 24.8%, 41.5%, 27.1%, and 34.4%, respectively. 
For the components of MS, prevalence of central obesity was 47.4%, impaired fasting 
glucose (IFG) 34.7%; hypertension 53.7%, low high-density lipoprotein (HDL) choles-
terol 34.2%, and hypertriglyceridemia 27.2%. 
Conclusions. Hypertension, central obesity, IFG, low HDL cholesterol, hypertriglyc-
eridemia, MS, and increased carotid artery intima-media thickness (IMT) were sig-
nificantly associated with NAFLD after adjustment for age and sex. With additional 
adjustment for body mass index (BMI), IMT and MS (depending on the prevalence ra-
tio that was investigated), the positive association between the NAFLD and increased 
IMT lost statistical significance, while that with body mass index (BMI) and MS re-
mained significant.
INTRODUCION
The prevalence of overweight and obesity has reached 
epidemic proportions, and is associated with many 
diseases and with increased all-cause mortality. Obe-
sity is associated with non-alcoholic fatty liver disease 
(NAFLD) [1] and with atherosclerosis and its cardiac 
sequelae, such as coronary artery disease and myocar-
dial infarction [2]. Different measures are used to de-
scribe body weight and its abnormalities; body-mass 
index (BMI) is the most commonly used. Waist circum-
ference and waist-to-hip ratio are likely better indica-
tors of visceral fat accumulation, but are of much less 
widespread use.
NAFLD is characterized by an excessive accumu-
lation of fat in the liver parenchyma of patients who 
have no history of alcohol abuse and it is now widely 
accepted as the most common cause of chronic liver 
disease in Western countries. The prevalence in the gen-
eral population has been estimated around 20-30% [3]. 
NAFLD ranges from simple steatosis to nonalcoholic 
steatohepatitis and cirrhosis [4]. Increasing severity is 
accompanied by decreasing reversibility of the disease 
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condition. NAFLD is strongly associated with obesity, 
type 2 diabetes, dyslipidemia, atherosclerosis, and is a 
risk factor for cardiovascular disease, both in adults and 
in adolescents [5-7].
To study atherosclerosis, carotid intima-media thick-
ness (IMT) is commonly used as noninvasive marker of 
atherosclerosis. Increased IMT is associated with the 
presence and severity of coronary atherosclerosis and 
cardiovascular disease [11]. In patients with NAFLD, 
IMT was found to be greatest in patients with nonalco-
holic steatohepatitis, intermediate in those with simple 
steatosis, and lowest in healthy controls matched for 
age, sex, and BMI [8]. 
In this population-based study we have investigated 
the prevalence of NAFLD, cardiovascular and metabol-
ic risk factors, and their association with atherosclerosis 
in a small city in Southern Italy.
MATERIALS AND METHODS
Setting and target population
The study was conducted from April 2009 to January 
2011 by the Associazione Calabrese di Epatologia/ACE 
(Hepatology Association of Calabria), in collaboration 
with the Istituto Superiore di Sanità (Italian National 
Institute of Health). The study protocol conforms to 
the ethical guidelines of the 1975 Declaration of Hel-
sinki (6th revision, 2008) and was approved by the eth-
ics committees of participating institutions.
This study was conducted among randomly selected 
adults in the city of Cittanova (population ~10 376), an 
inland town in the Calabria Region of Southern Italy. 
Earnings of most inhabitants of Cittanova are in the 
middle of the income range. Sex and age distributions 
are similar to those of Southern Italy in general. A sys-
tematic random sample of 1401 (1 every 7) subjects, 
aged 18-75 years, was selected from the census list up-
dated in December 2008. Of the 1401, 992 (70.8%) 
agreed to participate. Of the 992 participants 51.7% 
were females. Written informed consent was obtained 
from all participants. Biochemical markers and NAFLD 
were investigated in all study subjects and carotid IMT 
was measured in a sub-sample, using a systematic ran-
dom procedure (1 in 2.5).
Physical examination
Weight and height were measured without shoes and 
with light clothing, and BMI was calculated as body 
weight (kg) divided by the square of height (m2). Waist 
circumference was measured, during expiration, at the 
narrowest point between the lower rib and the iliac 
crest. Blood pressure was measured 3 times, after the 
subject had been seated for at least 10 minutes. The last 
2 measurements were averaged for analysis.
Biochemistry and threshold values
Blood samples were collected in the morning after an 
overnight fast. All blood tests were performed in the 
same laboratory within a few hours of sampling. Fast-
ing levels of glucose, triglycerides, total cholesterol and 
high density lipoprotein cholesterol were measured 
using a Vitros 950 automatic analyzer (Ortho Clinical 
Diagnostics, Raritan, New Jersey). Low density lipo-
protein cholesterol was calculated using the formula of 
Friedewald. 
Values used to define the different conditions were as 
follows: overweight: BMI 25-29.9 kg/m2; obesity, ≥ 30 
kg/m2; central obesity: waist circumference ≥ 102 cm in 
men and ≥ 88 cm in women; impaired fasting glucose 
(IFG): fasting glucose ≥ 100 mg/dL, ≤ 125 mg/dL; dia-
betes: fasting glucose ≥ 126 mg/dL or previous diagno-
sis and/or hypoglycemic therapy; hypertension: systolic 
blood pressure ≥ 130 mmHg or diastolic blood pressure 
≥ 85 mmHg or previous diagnosis and/or antihyperten-
sive therapy; hypertriglyceridemia: fasting triglycerides 
≥ 150 mg/dL, or ongoing therapy; low HDL cholesterol: 
< 40 mg/dL in men and < 50 mg/dL in women or ap-
propriate therapy; MS: presence of at least three of the 
aforementioned components.
Ultrasonographic studies
NAFLD was defined as ultrasonographically assessed 
fatty liver in individuals with alcohol consumption < 
140 g/week for women and < 210 g/week for men over 
a 2-year period prior to the study participation, without 
other causes of chronic liver disease and not assuming 
potentially steatogenic drugs.
Liver ultrasonography was performed on all partici-
pants by a single sonographer according to a standard 
protocol previously described [5]. All ultrasound exami-
nations were recorded. The sonographer, blinded to the 
weight status of the participants, was asked to reexamine 
100 recorded, randomly selected ultrasonograms after 1 
month. All initial NAFLD diagnoses were confirmed. 
Carotid artery ultrasonogaphy was performed, using 
a 7.5 MHz probe by a single operator and was recorded 
online [9]. Examination of IMT measurements was per-
formed by an operator blinded to the weight and clini-
cal status of participants. 
Statistical analysis
For statistical analysis, population characteristics 
were reported as proportions, medians and ranges for 
categorical and continuous variables, respectively. Sta-
tistical differences in proportions were evaluated us-
ing a c2 test; a P value < 0.05 defined significance. As 
NAFLD was highly prevalent, prevalence ratios (PR) 
were calculated using a regression model with robust 
variance and constant time at risk [10]. Analyses were 
carried out using the STATA/IC 13.1 statistical package.
RESULTS
Of the 992 subjects that agreed to participate, 125 
subjects scored positive for hepatitis B virus or anti-
hepatitis C virus antibodies or had an alcohol consump-
tion exceeding the established limit.
Characteristics of study participants are shown in 
Table 1. 41.5% (412 out of 992 participants) of the 
subjects were overweight and 27.1% (269) were obese; 
47.4% (470) showed central obesity. Overweight was 
more prevalent in males than in females [48.2% (478) 
vs 35.4% (351), P < 0.001], but obesity prevalence was 
similar (P > 0.05). The overall prevalence of NAFLD 
was 24.8% (246), being higher in males [28.3% (281)] 
than in females [21.6% (214)]. IFG was reported in 
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34.7% (344); 53.7% (533) suffered from hypertension; 
34.2% (339) had low HDL cholesterol; 27.2% (270) 
had hypertriglyceridemia; 34.4% (341) had MS. A me-
dian of 0.71 mm (range, 0-49-1.59) of IMT was deter-
mined in a subset of 344 subjects.
Table 2 shows the PRs of metabolic and cardiovascu-
lar risk factors and abnormalities according to presence 
of NAFLD and without the 125 subjects that scored 
positive for hepatitis B virus or anti-hepatitis C virus 
antibodies or that had a daily alcohol consumption ex-
ceeding the predetermined limits. In this analysis, we 
used BMI because of it being the most commonly used 
measure of body weight and the most useful for com-
parative purposes. All known cardiovascular risk factors 
were found in association with NAFLD. When we in-
vestigated the PRs of BMI, MS, and IMT adjusted for 
other variables (BMI, IMT and MS, depending on the 
PR that was investigated), in addition to age and sex, 
PRs were still significantly higher for BMI and MS, but 
not for IMT.
DISCUSSION
This is the first study that has been performed on 
NAFLD prevalence in an open population of appar-
ently healthy subjects in Southern Italy. The only other 
Italian study on NAFLD in Italy in a similar popula-
tion was done in a small city in Northern Italy [11], 
and was conducted between January 2002 and August 
2003. The overall prevalence of NAFLD in that study 
was 20%, a value lower than the 24.8% found in our 
study. Both values are consistent with NAFLD preva-
lence reported in Western countries (20-30%) [3]. As 
found in the previous Italian study, also in our study 
NAFLD was associated with MS components, and with 
MS itself. Regarding overweight and obesity, the values 
are higher than those in the general Italian adult popu-
lation [12], and we had already observed a significantly 
higher prevalence of overweight/obesity in adults from 
Southern versus Northern Italy.
In our study, after adjustment for several variables 
in addition to age and sex, the PRs for BMI and MS 
with regard to the presence of NAFLD remained 
higher, while the association of NAFLD with increased 
IMT disappeared. This suggests that the presence of 
NAFLD is not independently associated with increased 
carotid IMT, and that other cardiovascular risk factors 
may be more important in playing a causal role. Con-
flicting results have been reported about the association 
of NAFLD with increased IMT.
For example, in a multi-ethnic study, NAFLD was 
significantly associated with IMT, but the association 
lost significance after adjustment for BMI and waist 
circumference [13]. In a study in diabetic patients, no 
association was found [14]. On the other hand, a recent 
systematic review and meta-analysis suggested that 
NAFLD is a strong, independent predictor of cardio-
vascular disease [15]. Similarly, a Chinese study showed 
that NAFLD was positively associated with increased 
carotid IMT, independently of conventional risk factors 
and of MS [7]. A study in a large European population 
[16] showed that the association between NAFLD and 
carotid IMT, was independent of traditional risk factors 
and MS components. Among the possible reasons for 
these conflicting results are differences in the preva-
lence of effect modifiers, and differences in confound-
ers adjusted for. Eventually, one should also consider 
the possibility that aspects peculiar to this study popula-
tion, such as dietary elements, might dissociate the rela-
tion between NAFLD and IMT once NAFLD is associ-
ated with MS and its individual components.  Whatever 
the explanation(s), most of the results that have been 
reported, including ours, suggest that NAFLD may 
Table 2 
Prevalence ratios of the metabolic or cardiovascular risk factors 
or abnormalities in subjects with NAFLD compared to subjects 
without NAFLD and without the 125 subjects that scored positive 
for hepatitis B virus or anti-hepatitis C virus or had a daily alcohol 
consumption exceeding the predetermined limits (867 subjects)
Cardiometabolic  
risk factors
PR 
(95% confidence interval)
BMI (kg/m2) 1.10 (1.09-1.12)*
1.09 (1.06-1.11)**
IMT 2.83 (1.12-7.14)*
1.61 (0.62-4.19)**
Central obesity 2.69 (2.14-3.37)*
IFG and/or antihyperglycemic 
therapy
1.99 (1.58-2.50)*
Hypertension 2.24 (1.68-3.00)*
Low HDL cholesterol 1.64 (1.34-2.01)*
Hypertriglyceridemia 1.73 (1.39-2.15)*
MS 2.85 (2.26-3.59)*
1.68 (1.23-2.29)**
* Adjusted for age and sex. ** Adjusted for age, sex and other variables (BMI, 
IMT and MS, depending on the PR that was investigated). BMI: body mass 
index; HDL: high-density lipoprotein; IFG: impaired fasting glucose; IMT: intima-
media thickness; MS: metabolic syndrome; NAFLD: non-alcoholic fatty liver 
disease; PR: prevalence ratio.
Table 1
Overall prevalence of metabolic and cardiovascular abnormalities 
in the study participants (992 randomly selected adults aged 18-
75 years, Cittanova, Reggio Calabria, Southern Italy, 2009-2011)
Age (years)* 48.0 (17.0-75.0)
BMI (kg/m2)* 27.2 (14.9-52.8)
Overweight (%) 41.5
Obesity (%) 27.1
Waist circumference (cm)* 94.0 (58.0-137.0)
Central obesity (%) 47.4
IFG (%) 34.7
Hypertension (%) 53.7
Low HDL cholesterol (%) 34.2
Hypertriglyceridemia (%) 27.2
NAFLD total (%) 24.8
MS (%) 34.4
* For quantitative variables: median (range). For the other variables: 
percentage. BMI: body mass index; HDL: high-density lipoprotein; IFG: impaired 
fasting glucose; MS: metabolic syndrome; NAFLD: non-alcoholic fatty liver 
disease.
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be a useful marker for suspecting the presence of early 
atherosclerosis and, consequently, putting in place diag-
nostic and prophylactic measures that may be useful to 
prevent pathologic consequences.
Regarding the role that NAFLD may play, either 
directly indirectly, alone or in combination with other 
risk factors, in the pathogenesis of atherosclerosis and 
related cardiovascular diseases, it is known that obesity 
and atherosclerosis are precursors of endothelial dys-
function, coronary microvascular dysfunction and coro-
nary artery disease. All of the latter may be promoted by 
genetic factors [17-20]. It is tempting to speculate that 
in patients with NAFLD, the presence of these genet-
ic factors may also be involved in determining similar 
pathologic sequelae. It would be interesting to analyze 
this possibility in forthcoming studies.
Overall, our results confirm the close association be-
tween NAFLD and both BMI and MS, thus, suggest-
ing that once NAFLD is identified, individuals should 
undergo clinical examinations aimed at identifying si-
lent and/or undiganosed metabolic and cardiovascular 
diseases. Moreover, it appears highly desirable to com-
plement the present study with a longitudinal investiga-
tion in order to disclose the actual relationship between 
NAFLD and actual pathologic outcomes.
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